YU3501A - Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze - Google Patents

Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze

Info

Publication number
YU3501A
YU3501A YU3501A YU3501A YU3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A YU 3501 A YU3501 A YU 3501A
Authority
YU
Yugoslavia
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
YU3501A
Other languages
English (en)
Serbo-Croatian (sh)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU3501A publication Critical patent/YU3501A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
YU3501A 1998-07-21 1999-06-18 Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze YU3501A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
YU3501A true YU3501A (sh) 2005-06-10

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
YU3501A YU3501A (sh) 1998-07-21 1999-06-18 Zajedničko ordiniranje inhibitora acat i mmp za tretman oštećenja od ateroskleroze

Country Status (25)

Country Link
EP (1) EP1098662A2 (is)
JP (1) JP2002521328A (is)
KR (1) KR20010083134A (is)
CN (1) CN1310629A (is)
AP (1) AP2001002035A0 (is)
AU (1) AU4701799A (is)
BG (1) BG105162A (is)
BR (1) BR9912296A (is)
CA (1) CA2335062A1 (is)
CZ (1) CZ2001126A3 (is)
EA (1) EA200100153A1 (is)
EE (1) EE200100046A (is)
HR (1) HRP20010055A2 (is)
HU (1) HUP0102880A3 (is)
ID (1) ID30030A (is)
IL (1) IL140982A0 (is)
IS (1) IS5809A (is)
NO (1) NO20010291L (is)
OA (1) OA11584A (is)
PL (1) PL346011A1 (is)
SK (1) SK502001A3 (is)
TR (1) TR200100205T2 (is)
WO (1) WO2000004892A2 (is)
YU (1) YU3501A (is)
ZA (1) ZA200100294B (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
AU2003267991B2 (en) * 2002-07-11 2009-10-08 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
ATE207891T1 (de) * 1996-05-17 2001-11-15 Warner Lambert Co Biphenylsulfonamid matrix metalloproteinase inhibitoren
KR20000068414A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도

Also Published As

Publication number Publication date
CZ2001126A3 (cs) 2002-01-16
HRP20010055A2 (en) 2002-04-30
ID30030A (id) 2001-11-01
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
HUP0102880A2 (en) 2002-06-29
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A2 (en) 2000-02-03
WO2000004892A3 (en) 2000-05-18
ZA200100294B (en) 2002-01-10
AU4701799A (en) 2000-02-14
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
HUP0102880A3 (en) 2002-11-28
NO20010291L (no) 2001-01-18
CN1310629A (zh) 2001-08-29
EE200100046A (et) 2002-06-17
EP1098662A2 (en) 2001-05-16
IS5809A (is) 2001-01-12
EA200100153A1 (ru) 2001-08-27
AP2001002035A0 (en) 2001-03-31
TR200100205T2 (tr) 2001-05-21
PL346011A1 (en) 2002-01-14
KR20010083134A (ko) 2001-08-31
SK502001A3 (en) 2002-06-04
BG105162A (en) 2001-12-29

Similar Documents

Publication Publication Date Title
BG105162A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
AU2713600A (en) Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
IL137465A0 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
PT1011682E (pt) Contraceptivo hormonal
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
GB9804886D0 (en) Therapeutic combination
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
MXPA01005165A (es) Aparato de frenado de emergencia de modo doble y metodo para su uso.
HUP0103424A3 (en) Use of eletriptan for the prevention of migraine recurrence
DE59913590D1 (de) Verschleissauskleidung für Rohr- und/oder Kugelmühlen
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
WO1999002565A3 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
HU9801075D0 (en) Fixed-dose association of an angiotensinconverting enzyme inhibitor and of a calcium channel antagonist, method for preparation and use thereof in the treatment of cardiovascular illnesses
CA2322967A1 (en) Prophylactic, therapeutic agent for osteoporosis
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
MY140504A (en) Statin-mmp inhibitor combinations
ID26666A (id) Penggunaan agen untuk pencegahan penyakit gusi
IL152989A0 (en) Use of riluzole or its salts for preventing and treating ?noleukodystrophy
SE9802198L (sv) Dambinda
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
AU2002328400A1 (en) Remedial agent for cancer and cancer preventive
GB9810521D0 (en) Use of an agent in the manufacture of a medicament